GlassScriptPhysician profile
Jessica Stendel
NPI 1427042639
$3,838.86
in general payments reported to CMS, 2019-2025
32 companies · $517 in 2025
The $517 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $715 · 2022: $765 · 2023: $848 · 2024: $994 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.22 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $345.26 | 2022-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $322.44 | 2021-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Lilly USA, LLC | $193.23 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $178.15 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $172.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.40 | 2021-2023 | Stiolto Respimat, Spiriva Respimat, Synjardy |
| Amgen INC. | $157.75 | 2021-2025 | Repatha, Repatha, Prolia |
| Novo Nordisk INC | $122.34 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $122.21 | 2021-2024 | Gardasil, Gardasil 9, Vaxelis |
| Hologic Sales and Service, LLC | $114.92 | 2021-2025 | Thinprep 2000 Processor, Aptima |
| Amarin Pharma, INC. | $111.54 | 2021-2022 | |
| Exact Sciences Corporation | $109.20 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $98.93 | 2021-2024 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $83.22 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $81.55 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $77.36 | 2021 | |
| Sanofi Pasteur INC. | $53.65 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $45.10 | 2023-2024 | Crysvita |
| Lundbeck LLC | $39.99 | 2024 | Rexulti |
| Dexcom, INC. | $37.75 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $33.52 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.47 | 2021 | |
| Radius Health, INC. | $26.65 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $21.26 | 2022 | |
| Astellas Pharma US INC | $20.21 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $16.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.68 | 2022 | |
| Seqirus USA INC | $14.92 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Paratek Pharmaceuticals, INC. | $14.53 | 2025 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $14.41 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Stendel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.